Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.

Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V BLOOD. 2018; 131(11): 1206-1218.

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.

Sasse, S; Goergen, H; Plütschow, A; Böll, B; Eichenauer, DA; Fuchs, M; Behringer, K; Zijlstra, JM; Greil, R; Markova, J; Topp, MS; Meissner, J; Neubauer, A; Baues, C; Engert, A; Borchmann, P; von Tresckow, B; J Clin Oncol. 2018; 36(25): 2603-2611.

Austrian recommendations for the management of polycythemia vera.

Burgstaller, S; Buxhofer-Ausch, V; Sliwa, T; Beham-Schmid, C; Gastl, G; Geissler, K; Melchardt, T; Krauth, M; Krippl, P; Petzer, A; Rumpold, H; Wölfler, A; Gisslinger, H; Wien Klin Wochenschr. 2018; 130(17-18):535-542

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wöhrer, S; Wölfler, A; Gisslinger, H; Wien Klin Wochenschr. 2018; 130(17-18): 495-504.

PET-guided treatment in patients with advanced-stage Hodgkins lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann, P; Goergen, H; Kobe, C; Lohri, A; Greil, R; Eichenauer, DA; Zijlstra, JM; Markova, J; Meissner, J; Feuring-Buske, M; Hüttmann, A; Dierlamm, J; Soekler, M; Beck, HJ; Willenbacher, W; Ludwig, WD; Pabst, T; Topp, MS; Hitz, F; Bentz, M; Keller, UB; Kühnhardt, D; Ostermann, H; Schmitz, N; Hertenstein, B; Aulitzky, W; Maschmeyer, G; Vieler, T; Eich, H; Baues, C; Stein, H; Fuchs, M; Kuhnert, G; Diehl, V; Dietlein, M; Engert, A; Lancet. 2018; 390(10114): 2790-2802.

Factor VII deficiency in major artery occlusion stroke.

Pikija, S; Gampenrieder, SP; Millesi, K; Pilz, G; Weis, S; Mutzenbach, JS AM J HEMATOL. 2018; 93(6): 843-845.

Endolysosomal protease susceptibility of Amb a 1 as a determinant of allergenicity.

Wolf, M; Aglas, L; Twaroch, TE; Steiner, M; Huber, S; Hauser, M; Hofer, H; Parigiani, MA; Ebner, C; Bohle, B; Briza, P; Neubauer, A; Stolz, F; Wallner, M; Ferreira, F; J Allergy Clin Immunol. 2018; 141(4): 1488-1491.e5.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R; Ann Hematol. 2018; 97(9):1745

Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

Bolger, GT; Licollari, A; Tan, A; Greil, R; Pleyer, L; Vcelar, B; Majeed, M; Sordillo, P; Anticancer Res. 2018; 38(1): 12-130.

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer, F; Thaler, J; Piringer, G; Hackl, H; Pleyer, L; Hufnagl, C; Weiss, L; Greil, R; BMC Cancer. 2018; 18(1): 11